Key Financial Performance (Standalone)

Quarterly Performance (YoY Comparison):

  • Revenue from Operations: ₹756.3 Crore (up 37.1% from ₹551.7 Crore in Q1 FY26)
  • EBITDA: ₹111.7 Crore (up 60.7% from ₹69.5 Crore in Q1 FY26)
  • PAT: ₹64.5 Crore (up 89.9% from ₹34.0 Crore in Q1 FY26)
  • EBITDA Margin: 14.6% (vs 12.4% in Q1 FY26)
  • PAT Margin: 8.4% (vs 6.1% in Q1 FY26)

Sequential Performance (QoQ Comparison):

  • Revenue from Operations: ₹756.3 Crore (up 22.1% from ₹619.5 Crore in Q4 FY26)
  • EBITDA: ₹111.7 Crore (up 18.5% from ₹94.3 Crore in Q4 FY26)
  • PAT: ₹64.5 Crore (up 21.2% from ₹53.2 Crore in Q4 FY26)

Segment Highlights

Pharmaceuticals Business:

  • Revenue growth: 43% YoY
  • EBIT growth: 72% YoY
  • Non-Ibuprofen products contributed 43% of Pharma revenue (up from 36% in Q1 FY26)
  • Key performing APIs: Paracetamol, Pantoprazole, Metformin, Fenofibrate
  • Paracetamol capacity utilization improved to 65% (from 60% in previous quarter)

Chemicals Business:

  • Revenue growth: 29% YoY
  • EBIT growth: 193% YoY

Export Performance

  • Exports contributed 28.5% of total revenue (up from 24.4% in Q1 FY26)
  • Reflects growing traction across international markets

Regulatory Approval

  • Clopidogrel API product received NMPA approval in China
  • Company already holds valid CEP for this product
  • Expands access to Chinese pharmaceutical market

Management Commentary

Mr. Vikas Gupta, Joint Managing Director, commented that this represents a record quarterly performance with highest-ever revenue. Growth was achieved despite geopolitical uncertainties, supply chain disruptions, and inflationary pressures across select raw materials. Margin expansion was supported by improved capacity utilization, favourable product mix, and operational efficiencies.

Forward Outlook

Company remains focused on:

  • Scaling portfolio
  • Improving product mix
  • Enhancing capacity utilization
  • Expanding presence across value-added APIs and specialty chemicals
  • Building on current momentum for sustainable long-term growth

Safe Harbor Statement

Forward-looking statements are based on assumptions and subject to risks including industry downtrend, political/economic changes, tax laws, litigation, labor relations, exchange rate fluctuations, technological changes, and other costs. Company does not guarantee fulfillment of these statements.